Cargando…
Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients
The clinical characteristics of lung cancer in patients with idiopathic pulmonary fibrosis (IPF) differ from those of lung cancer in patients without IPF. Thus, we aimed to evaluate the impact of IPF on the clinical course of patients with lung cancer. Clinical data of IPF patients with lung cancer...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050293/ https://www.ncbi.nlm.nih.gov/pubmed/33859288 http://dx.doi.org/10.1038/s41598-021-87747-1 |
_version_ | 1783679571020742656 |
---|---|
author | Kim, Ho Cheol Lee, Seonjeong Song, Jin Woo |
author_facet | Kim, Ho Cheol Lee, Seonjeong Song, Jin Woo |
author_sort | Kim, Ho Cheol |
collection | PubMed |
description | The clinical characteristics of lung cancer in patients with idiopathic pulmonary fibrosis (IPF) differ from those of lung cancer in patients without IPF. Thus, we aimed to evaluate the impact of IPF on the clinical course of patients with lung cancer. Clinical data of IPF patients with lung cancer (n = 122) were compared with those of patients with lung cancer without IPF (n = 488) matched by age, sex, histopathology, stage, and date of diagnosis of lung cancer. The median follow-up period after diagnosis of lung cancer was 16 months. Among patients with IPF, the mean age was 68 years, 95.9% were male, 93.2% were ever-smokers, and squamous cell carcinoma was the most common cancer type (48.4%). The IPF group had poorer lung function and lower lobe predominance of lung cancer than the no-IPF group. The IPF group showed a poorer prognosis than the no-IPF group (5-year survival rate: 14.5% vs. 30.1%, respectively; P < 0.001), even after adjusting for lung function and regardless of the treatment method. Among patients with IPF, 16.8% experienced acute exacerbation within 1 month after treatment of lung cancer. The treatment outcome of patients with lung cancer and IPF was generally unfavorable, and acute exacerbation triggered by treatment frequently occurred. |
format | Online Article Text |
id | pubmed-8050293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-80502932021-04-16 Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients Kim, Ho Cheol Lee, Seonjeong Song, Jin Woo Sci Rep Article The clinical characteristics of lung cancer in patients with idiopathic pulmonary fibrosis (IPF) differ from those of lung cancer in patients without IPF. Thus, we aimed to evaluate the impact of IPF on the clinical course of patients with lung cancer. Clinical data of IPF patients with lung cancer (n = 122) were compared with those of patients with lung cancer without IPF (n = 488) matched by age, sex, histopathology, stage, and date of diagnosis of lung cancer. The median follow-up period after diagnosis of lung cancer was 16 months. Among patients with IPF, the mean age was 68 years, 95.9% were male, 93.2% were ever-smokers, and squamous cell carcinoma was the most common cancer type (48.4%). The IPF group had poorer lung function and lower lobe predominance of lung cancer than the no-IPF group. The IPF group showed a poorer prognosis than the no-IPF group (5-year survival rate: 14.5% vs. 30.1%, respectively; P < 0.001), even after adjusting for lung function and regardless of the treatment method. Among patients with IPF, 16.8% experienced acute exacerbation within 1 month after treatment of lung cancer. The treatment outcome of patients with lung cancer and IPF was generally unfavorable, and acute exacerbation triggered by treatment frequently occurred. Nature Publishing Group UK 2021-04-15 /pmc/articles/PMC8050293/ /pubmed/33859288 http://dx.doi.org/10.1038/s41598-021-87747-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Kim, Ho Cheol Lee, Seonjeong Song, Jin Woo Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients |
title | Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients |
title_full | Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients |
title_fullStr | Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients |
title_full_unstemmed | Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients |
title_short | Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients |
title_sort | impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050293/ https://www.ncbi.nlm.nih.gov/pubmed/33859288 http://dx.doi.org/10.1038/s41598-021-87747-1 |
work_keys_str_mv | AT kimhocheol impactofidiopathicpulmonaryfibrosisonclinicaloutcomesoflungcancerpatients AT leeseonjeong impactofidiopathicpulmonaryfibrosisonclinicaloutcomesoflungcancerpatients AT songjinwoo impactofidiopathicpulmonaryfibrosisonclinicaloutcomesoflungcancerpatients |